Filter by year
View News and/or Blogs
CRO Alliance Pharma’s Executive Team Grows by Four, Supporting Bioanalytical and CMC Testing Expansions

News - Alliance Pharma (Alliance), a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing onboard a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO). These leaders will support continued global expansion, which includes Alliance’s recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC and new bioanalytical laboratory opening in Australia in November.

21 September 2022
U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia

News - Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.

11 August 2022
U.S. Alliance Pharma Acquires UK-based LGC’s Drug Development Solutions Business (DDS)

News - Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.

13 July 2022
Alliance Pharma agrees to acquire LGC’s Drug Development Solutions Business Unit

News - Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners. Backed by Ampersand and KKR, Alliance and DDS plan to expand the company’s geographic reach, broaden its laboratory capabilities and expand its service portfolio. The transaction is subject to regulatory approvals and expected to be completed in Q2 2022.

17 May 2022
Drug Development Solutions offers regulated bioanalysis on the SCIEX TripleTOF® 6600 High-Resolution Mass Spectrometry platform

News - Drug Development Solutions is pleased to announce the extension of its regulated bioanalytical LC-MS service through the implementation of a high-resolution mass spectrometer, the SCIEX TripleTOF® 6600 LC-MS/MS System.

25 November 2020